Dr. Amanda M. Parkes

Hematology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Amanda Parkes is a Hematologist practicing medicine in Cary, North Carolina.

Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum.

She is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in WI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant, Adjuvant Therapy
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Aromatase Inhibitor
Study Phase: Phase 2
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: August 14, 2024
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Champlin is a Hematologist practicing medicine in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Amanda M. Parkes

How do I make an appointment with Dr. Amanda M. Parkes?

You can book an appointment with Dr. Amanda M. Parkes by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amanda M. Parkes a top-rated expert for PIK3CA-Related Overgrowth Spectrum?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amanda M. Parkes is classified as an Experienced expert for PIK3CA-Related Overgrowth Spectrum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amanda M. Parkes specialize in?

While Dr. Amanda M. Parkes is a Hematology, they have specific expertise in PIK3CA-Related Overgrowth Spectrum. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Amanda M. Parkes participate in research or clinical trials?

Yes. Dr. Amanda M. Parkes has published 29 articles and abstracts on conditions like PIK3CA-Related Overgrowth Spectrum. You can view a list of Dr. Amanda M. Parkes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amanda M. Parkes accept my insurance?

Dr. Amanda M. Parkes accepts most major insurance plans, including Humana. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parkes's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile